Deals Rumor Mill: Novartis, Disney, Shell
Several drugmakers are considering making bids for ThromboGenics NV, an European eye-medication company worth up to $1.3 billion, according to a Monday report from Bloomberg. Novartis AG, which is considered the...To view the full article, register now.
Already a subscriber? Click here to view full article